Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | NRAS wild-type |
Therapy | Panitumumab |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS wild-type | colorectal cancer | predicted - sensitive | Panitumumab | FDA approved - On Companion Diagnostic | Actionable | Vectibix (panitumumab) is FDA approved for metastatic colorectal patients that are NRAS wild-type, as detected by a companion diagnostic (FDA.gov). | detail... detail... |
NRAS wild-type | colorectal cancer | predicted - sensitive | Panitumumab | Phase III | Actionable | In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920). | 26341920 |
PubMed Id | Reference Title | Details |
---|---|---|
(26341920) | Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. | Full reference... |
Full reference... | ||
Vectibix (panitumumab) FDA Drug Label | Full reference... |